From the Section on Cellular Neurobiology, Laboratory
of Developmental Neurobiology, NICHD, National Institutes of
Health, Bethesda, Maryland 20892 and the ¶ Combinatorial Chemistry
Department, University of California, Berkeley, California 94704
Received for publication, July 18, 2002, and in revised form, November 4, 2002
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The potent peptidic inhibitor, Y1, of the
basic residue-specific yeast aspartyl protease, yapsin 1, was
synthesized and characterized. The inhibitor was based on the peptide
sequence of a cholecystokinin13-33 analog that yapsin 1 cleaved with an efficiency of 5.2 × 105
M Yeast aspartyl protease 3 was the third aspartyl
protease to be cloned from Saccharomyces cerevisiae (1)
after saccharopepsin and barrierpepsin. It was cloned based on its
ability to partially suppress the pro- Since the discovery of yapsin 1, a large body of work has
emerged describing its nature with respect to its physical and chemical properties and has been comprehensively reviewed in the Handbook of Proteolytic Enzymes (4). To further investigate the mechanism of action of the enzyme, we have attempted to crystallize yapsin 1 but
have been unsuccessful. Although purification of yapsin 1 by classical
procedures has been accomplished (10, 11), the presence of excess
N-linked glycosylation on yapsin 1 interfered with the
crystallization process. In addition, the deglycosylated yapsin 1 was
unstable. For more traditional aspartyl proteases, inhibitor columns
are often used to facilitate purification, and inhibitors are used to
stabilize the protease during crystallization. However, pepstatin A, an
aspartyl protease-specific inhibitor, is the only compound reported to
inhibit yapsin 1 and shows only modest inhibition
(Ki APP = 0.4 µM (12). We
therefore undertook to synthesize a more potent inhibitor that could be used to purify yapsin 1 and subsequently stabilize the deglycosylated form of yapsin 1 during crystallization. The development of new, more
potent inhibitors for members of the yapsin subclass of aspartyl proteases is also relevant for the treatment of human disease. In this
respect, the discovery that one of the secreted aspartyl proteases,
Sap9p, of the opportunistic yeast, C. albicans, is a member
of the yapsin family (7) renders the use of a specific inhibitor of
Sap9p potentially important in the control of its pathogenesis.
Synthesis of Inhibitor
Materials were obtained from commercial suppliers and employed
without further purification unless otherwise stated.
Dihydropyranyl resin was purchased from NovaBiochem (San Diego,
CA). Anhydrous N,N-dimethylformamide
(DMF)1 and
N-methylpyrrolidinone (NMP) were purchased from Aldrich. The
following solvents were distilled under N2 from specified drying agents: tetrahydrofuran and diethyl ether from
sodium/benzophenone ketyl and methylene chloride
(CH2Cl2) and dichloroethane and pyridine from
calcium hydride. For the general solid phase work-up procedure, excess
reagent and the reaction solution were filtered away from support-bound
material using polypropylene cartridges with 70-µ PE frits (Speed
Accessories) attached to Teflon stopcocks. Cartridges and stopcocks
were purchased from Applied Separations (Allentown, PA). Immobilized
diaminodipropylamine gel and the polystyrene columns (1-5-ml bed
volumes) for affinity column chromatography were purchased from Pierce.
For a detailed description of the chemical reactions and compound
characterization see the supplemental data. Compound 1 shown
in the scheme in Fig. 1 is referred to as
the inhibitor Y1. Compound 2, an analog of Y1 used for coupling to agarose beads, is shown in the scheme in Fig. 2 and is referred to as
the inhibitor Y2.
1 s
1 (Olsen, V., Guruprasad,
K., Cawley, N. X., Chen, H. C., Blundell, T. L., and
Loh, Y. P. (1998) Biochemistry 37, 2768-2777). The apparent Ki of Y1 for the inhibition of yapsin 1 was determined to be 64.5 nM, and the mechanism is
competitive. Y2 was also developed as an analog of Y1 for coupling to
agarose beads. The resulting inhibitor-coupled agarose beads were
successfully used to purify yapsin 1 to apparent homogeneity from
conditioned medium of a yeast expression system. Utilization of this
new reagent greatly facilitates the purification of yapsin 1 and should
also enable the identification of new yapsin-like enzymes from
mammalian and nonmammalian sources. In this regard, Y1 also efficiently inhibited Sap9p, a secreted aspartyl protease from the human pathogen, Candida albicans, which has specificity for basic residues
similar to yapsin 1 and might provide the basis for the prevention or control of its virulence. A single-step purification of Sap9p from
conditioned medium was also accomplished with the inhibitor column.
N-terminal amino acid sequence analysis yielded two sequences indicating that Sap9p is composed of two subunits, designated here as
and
, similar to yapsin 1.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-mating factor processing
defect in yeast mutants that lacked the normal processing enzyme,
kex2p, a subtilisin-like serine protease (2). The ability to
correctly process the pro-
-mating factor demonstrated that this new
aspartyl protease could cleave a prohormone at paired basic residue
cleavage sites. This identified the new enzyme as a unique member of
the aspartyl protease family of endoproteases whose specificity for
basic residues was in direct contrast to all other aspartyl proteases
whose classical specificity for hydrophobic residues was well
documented (3). Since its discovery, yeast aspartyl protease 3 has been
renamed yapsin 1 (4) to represent it as the first cloned member of this
novel subclass of aspartyl proteases. This subclass currently includes five members, yapsin 1, yapsin 2 (5), and yapsin 3 (6) from S. cerevisiae, Sap9p from Candida albicans (7), and the
previously described pro-opiomelanocortin converting enzyme (now named
yapsin A) (8) from bovine pituitary secretory granules (9).
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
View larger version (21K):
[in a new window]
Fig. 1.
Scheme of the design and synthesis of
inhibitor Y1. Compound 1 was synthesized based on the
sequence of a CCK13-33 peptide analog according to the
scheme outlined here. See the supplemental data for details of chemical
reactions and compound characterization. Compound 1 is
referred to as the inhibitor Y1 used in the inhibitor
studies. a, TBHP, (L)-DIPT, Ti(OiPr)4, MS3A,
CH2Cl2, 40 °C, 73% yield, >95%
enantiomeric purity; b, Ti(OiPr)4, BzOH,
CH2Cl2, 88% yield; c,
2,2-dimethoxypropane, pyridinium
p-toluenesulfonate, acetone, room temperature;
d, H2NNH2, EtOH, 80 °C;
e, (Boc)2O, EtOH-1N NaOH, room temperature, 98%
yield/three steps; f, pTsCl, pyr, room temperature, 98%
yield; g, NaN3, Me2SO;
h, PPTs, 90% MeOHaq, 55% yield/two steps; i,
pTsCl, pyr, 0 °C, 77%; j, dihydropyranyl resin,
PPTs, 60 °C; k, BuNH2, 80 °C;
l, Boc-Arg
(2,2,5,7,8-pentamethylchroman-6-sulfonyl), HATU,
iPr2EtN, NMP; m, SnCl2, PhSH,
Et3N, tetrahydrofuran; n, standard peptide
synthesis; o, trifluoroacetic acid, H2O.
View larger version (13K):
[in a new window]
Fig. 2.
Scheme of the synthesis of inhibitor-coupled
agarose beads. Compound 2, an analog of the inhibitor
Y1 described in Fig. 1, was coupled to agarose beads
according to the scheme outlined here and described under "Materials
and Methods" to generate the affinity matrix. a, DMF, pH
4.7 buffer; b, piperidine, NMP; c, DMF pH 4.7 buffer.
Ki Determination of Inhibitor Y1 for Yapsin 1
We utilized an internally quenched fluorescent substrate, Abz-Arg-Val-Lys-Arg-Gly-Leu-Ala-Tyr(NO2)-Asp-OH (Bachem, Torrance, CA) to determine the Ki of Y1 for yapsin 1. This substrate was previously developed (13) as a substrate for furin, a subtilisin-like proprotein convertase (14); however, the Lys-Arg motif within this substrate is a well characterized yapsin 1 cleavage site (15). We first determined the Km and Vmax of yapsin 1 for this substrate as follows. Yapsin 1 was purified from a yeast expression system as described previously (11). Purified yapsin 1 (~7 nM; ~37 ng) was incubated with 5-40 µM of the substrate at 37 °C in 100 µl of 0.1 M ammonium acetate, pH 4.0. 15-µl aliquots were removed at 5, 10, 20, 30, 40, and 60 min and added to 1 ml of 50 mM Tris-HCl, pH 7.5, to stop the enzymatic reaction. The samples were kept on ice until assayed for fluorescence in a Perkin-Elmer LS-5 luminescence spectrometer (emission, 320 nm; excitation, 425 nm). A nonlinear regression fit to each time course allowed the calculation of the initial rate of enzymatic activity at each substrate concentration and a Lineweaver-Burk plot of 1/Vo versus 1/[S] was generated to determine Km and Vmax. These experiments were performed three times.
Preliminary experiments that included "recovery of activity" (16) and Lineweaver-Burk plots (data not shown) indicated that Y1 was a reversible competitive inhibitor of yapsin 1. To determine the Ki, purified yapsin 1 (~7 nM) was incubated with dilutions of Y1 (ranging from 250 to 15.6 nM) in 98 µl 0.1 M ammonium acetate, pH 4.0, for 20 min at room temperature. 2 µl of 0.5 mM substrate (final substrate concentration, 10 µM) were then added, and the reactions were allowed to continue for 10 min at 37 °C. 15 µl were then assayed for fluorescence as described above. This experiment was performed three times. A Dixon plot of 1/Vo versus [I] was generated from which Ki was calculated using the derivation of the Lineweaver-Burk equation for competitive inhibition and the Km and Vmax parameters determined in the previous experiment.
Preparation of Affinity Column
Preparation of Inhibitor Y2 for Attachment to Affinity Column-- Inhibitor Y2 was prepared from support-bound tosylate 11 (Fig. 1) (100 mg, 48.8 µmol, 0.488 mmol/g) according to the solid phase synthesis methods to prepare inhibitor Y1 up through coupling Fmoc-Val (see the supplemental data). At this stage Fmoc-Arg (2,2,5,7,8-pentamethylchroman-6-sulfonyl) was coupled using 0.3 M Fmoc-Arg (2,2,5,7,8-pentamethylchroman-6-sulfonyl), 0.3 M PyBOP, 0.3 M HOAt, and 0.9 M iPr2EtN in NMP with shaking overnight. The resin was washed with NMP (four times), tetrahydrofuran (twice), CH2Cl2 (three times), and ether (three times), and then the resin was treated with 20% piperidine in NMP solution for 30 min. The resin was then treated with 0.3 M 4-carboxybenzaldehyde, 0.3 M PyBOP, 0.3 M HOAt, and 0.9 M iPr2EtN in NMP with shaking overnight. Inhibitor Y2 was cleaved from the solid support using 95:5 trifluoroacetic acid/H2O for 30 min followed by rinses with 95:5 trifluoroacetic acid/H2O (once) and CH2Cl2 (twice) and then concentration under reduced pressure. The mixture was purified by reverse phase HPLC as described for inhibitor Y1 (see the supplemental data), and the mass was confirmed by mass spectrometry. HPLC purification provided 17.6 mg (16.1 µmol) of inhibitor Y2 (Fig. 2). High resolution mass spectrometry (fast atom bombardment) calculated for [M]+ (C50H89N15O10S) was 1092.672650, and found was 1092.671582.
Inhibitor-coupled Agarose Beads-- Diaminodipropylamine gel (2 ml, ~40 µmol) was packed into a 5-ml polystyrene column. The gel was allowed to settle for 30 min, and then the gel was equilibrated and drained with 5 column volumes of conjugation buffer. To the gel was added 2-[(N-fluorenemethyloxycarbonyl) aminooxy] acetic acid N-hydroxysuccinimide 15 (Fig. 2) (162 mg, 0.40mmol) in DMF (2.0 ml) and pH 4.7 buffer (100 µl). Mixing was then carried out by rotating the suspension at room temperature for 12 h. The gel was then washed with DMF (three times). The loading level of the gel was determined by Fmoc quantitation (gel total, 33.4 µmol, 0.0309 mequiv/g, 84% loading efficiency based on a 20 µequiv/ml loading level of diaminodipropylamine gel). The gel was treated with 20% piperidine in NMP for 3 h and then was washed with DMF (three times). To the resulting gel 16 (Fig. 2) was added inhibitor Y2 (Fig. 2) (12.1 mg, 11.1 µmol) in a solution of DMF (1.0 ml) and pH 4.7 buffer (100 µl). Mixing was then carried out by rotating the suspension at room temperature for 12 h. The resulting inhibitor coupled agarose beads (Fig. 2, compound 3) were then washed with DMF (three times) and pH 4.7 buffer (three times).
Purification of Yapsin 1 by Affinity Chromatography
The inhibitor-coupled agarose beads (Fig. 2, compound 3) were equilibrated with equilibration buffer (0.1 M ammonium acetate, pH 4.0). A C-terminally truncated form of yapsin 1, lacking its GPI membrane anchor, described previously (17), was overexpressed and secreted into the culture medium from a yeast strain engineered to express this form of the enzyme. The culture supernatant was adjusted to pH 7.0 with 1 M Tris/Cl and concentrated by batch application to DEAE-Sepharose beads. After washing, the bound protein was eluted with 0.2 M NaCl and aliquoted. A 0.9-ml aliquot of the concentrated medium enriched in yapsin 1 was adjusted to 0.1 M ammonium acetate, pH 4.0, and applied to the inhibitor column. After collecting the flow through, the column was washed with 6 × 0.9 ml of equilibration buffer followed by 6 × 0.9 ml of equilibration buffer containing 0.5 M NaCl. The yapsin 1 was eluted with 9 × 0.9 ml of 20 mM Tris/Cl, pH 8.5, containing 2 M LiBr.
Yapsin 1 immunoreactivity was assayed by Western blot analysis. 10 µl of each sample were fractionated by denaturing polyacrylamide gel electrophoresis on 4-12% NuPAGE gels under reducing conditions using MES as running buffer (Invitrogen). After transferring the protein to nitrocellulose, the blots were probed with yapsin 1 antiserum MW283 (17) at 1:10,000, and the signal was visualized by enhanced chemiluminescence. Yapsin 1 enzymatic activity was assayed by incubating 1 µl of each fraction from the purification procedure with 25 µg of rat proenkephalin (pro-Enk) (5 mg/ml), purified as described previously (18), in 0.1 M ammonium acetate, pH 4.0, for 12 h. The reaction volume was 100 µl. Yapsin 1 cleaves rat pro-Enk efficiently to release its N terminus, syn-enkephalin-Lys (pro- Enk1-74).2 20 µl of each reaction was analyzed by colloidal Coomassie Blue staining after denaturing polyacrylamide gel electrophoresis on 4-12% NuPAGE gels under reducing conditions using MES as running buffer.
Analysis of Affinity-purified Yapsin 1
Fractions containing pro-Enk cleaving activity and yapsin 1 immunoreactivity were pooled and concentrated by centrifugation through 30-kDa Filtron Nanosep membranes. An aliquot of the final sample (~200 ng) was deglycosylated by endoglycosidase H as described previously (17) and analyzed by Western blot analysis and silver staining. 10 µg of the starting material was also analyzed by Coomassie Blue staining. Specific activity measurements were carried out on the starting material and on the final purified yapsin 1 using the quenched fluorescent substrate. Briefly, yapsin 1 enzymatic activity was assayed by incubating 2 µl from both samples with 10 µM of the quenched fluorescent substrate in 100 µl of 0.1 M ammonium acetate, pH 4.0, for 20min at 37 °C. 900 µl of 50 mM Tris-HCl, pH 7.5, were added to the reaction, and the fluorescence was determined as described above. The units of fluorescence were then corrected to units/µg/min.
Inhibition of Sap9p Cleavage of Proenkephalin by Inhibitor Y1
A C-terminally truncated form of secreted aspartyl protease 9 (Sap9p), lacking its GPI membrane anchor, was expressed in a Pichia pastoris expression system. Sap9p was expressed and secreted into the culture medium after induction, and the culture supernatant was concentrated by centrifugation filtration through 30-kDa Filtron Macrosep membranes. The presence of Sap9p in the induced preparation was confirmed by Coomassie Blue staining of an induced protein of the expected size after SDS-PAGE and by the ability of the induced preparation alone to cleave adrenocorticotropin hormone1-39 with identical specificity to that of yapsin 1.2 To test the inhibitor against Sap9p, we used purified rat pro-Enk as a substrate. Aliquots of the conditioned medium containing Sap9p were preincubated with Y1 (1-100 µM) in 0.1 M ammonium acetate, pH 4.0. for 20 min at room temperature, after which 25 µg of purified rat pro-Enk was added, and the reaction continued for 12 h at 37 °C. The reaction volume was 100 µl. The controls included omission of enzyme, omission of inhibitor, or addition of 2.5 mM pepstatin A, a specific inhibitor of aspartyl proteases. After incubation, 20 µl of each reaction was analyzed by colloidal Coomassie Blue staining after denaturing polyacrylamide gel electrophoresis on 4-12% NuPAGE gels under reducing conditions using MES as running buffer (Invitrogen).
Purification of Sap9p by Affinity Chromatography
10 ml of conditioned medium containing Sap9p was adjusted to pH
4.0 with 1 M ammonium acetate, pH 4.0. The sample was
centrifuged at 13,000 × g for 5 min to remove
particulate matter, and the supernatant was applied to the inhibitor
column (Fig. 2, compound 3). The flow through fraction
was reapplied twice before continuing with the purification procedure
exactly as described for the purification of yapsin 1. 1-µl aliquots
from each fraction were assayed for pro-Enk processing activity.
Fractions E2 and E3 were pooled and concentrated by centrifugation
filtration through 30-kDa Nanosep filters, and an aliquot of the final
sample was analyzed by Coomassie Blue. In addition, 5 µg of purified
Sap9p were run on a denaturing 4-12% NuPAGE gel, transferred to
polyvinylidene difluoride, and subjected to Edman degradation using an
Applied Biosystems model 470A protein sequencer with an on-line
phenylthiohydantoin analyzer.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Synthesis of Inhibitor-- The inhibitor Y1 (Fig. 1, compound 1) was identified upon the preparation and screening of a focused library of 45 compounds based upon a known yapsin 1 substrate, RVSMIKNR. The key design feature was to replace the Lys-Asn dipeptide in the peptide substrate with the stable hydroxyethylamine peptide isostere incorporating a lysine side chain at the P1 position. The hydroxyethylamine isostere has been extensively used for the inhibition of the HIV-1 protease with several marketed AIDS drugs based upon this template. However, these isosteres incorporate hydrophobic side chains at the P1 position, and to our knowledge, the incorporation of basic side chains at the P1 position has not previously been reported.
The preparation of Y1 is shown in Fig. 1 as compound
1. Asymmetric Sharpless epoxidation of allylic alcohol 4 (19) provides epoxy alcohol 5 in 73% yield
with >95% enantiomeric purity as measured by 1H
NMR of the corresponding Mosher ester. Benzoyloxy diol 6 was
then prepared by treating epoxy alcohol 5 with
(i-PrO)2Ti(OBz)2. Acetalization with 2,2-dimethoxy propane and
p-toluenesulfonic acid was followed by exchange of the
phthalimide group for the Boc group under standard conditions to
provide alcohol 7. Treatment of alcohol 7 with
toluenesulfonyl chloride in pyridine provided the tosylate
8. Azide displacement was followed by removal of the
isopropylidene group to provide diol 9. Selective tosylation
of the primary alcohol with toluenesulfonyl choride in pyridine
provided intermediate 10 for loading onto the solid support.
Intermediate 10 was then attached to the support using
commercially available dihydropyranyl substituted resin (20) to provide
support-bound inhibitor 11. The synthesis of Y1
was then performed according to previously developed solid phase
synthesis methods (21). Displacement of the primary tosylate with
butylamine was followed by acylation of the amine with
-N-Boc-Arg to provide supported intermediate 12. Reduction of the azide with SnCl2, PhSH, and
Et3N provided amine 13, which was then coupled
with N-Fmoc-Ile, N-Fmoc-Met, N-Fmoc-O-t-Bu-Ser, N-Fmoc-Val, and
N-Boc-Arg using standard peptide synthesis methods to
provide the support-bound inhibitor 14. Removal from support
with concomitant side chain deprotection was accomplished by treatment
with 95:5 trifluoroacetic acid/H2O to provide
Y1.
Ki Determination of Y1 for Yapsin 1--
A Lineweaver-Burk
plot of 1/Vo versus 1/[S] yielded a
straight line with the following equation, y = 0.87x + 0.036, r2 = 0.98 (Fig.
3A). From this equation, the
Km was calculated as 24.2 µM, and
Vmax was calculated as 27.8 fluorescent
units/min (or 751 units/µg/min). In the presence of Y1,
yapsin 1 activity was inhibited in a dose-dependent manner,
and when plotted in the form of a Dixon plot,
1/Vo versus [I], a straight line was obtained with the following equation, y = 0.0014x + 0.1274, r2 = 0.99 (Fig.
3B). From the derivation of the Dixon plot, competitive inhibition predicts that y = 1/Vmax(1 + Km/[S]) = 0.123, when x = 0. Our data therefore fits well with
that of a competitive inhibitor because y = 0.1274 when
x = 0. Also from the equation for competitive
inhibition, when y = 0, x = Ki(1 + [S]/Km), from which
Ki calculates as 64.5 nM.
|
Preparation of the Inhibitor-coupled Agarose Beads-- To prepare the affinity column for yapsin purification, the diaminodipropylamine (diaminodipropylamine) form of Sephadex was coupled with active ester 15. Removal of the Fmoc group then provides the alkoxylamine derivatized agarose beads 16, which was then covalently linked to inhibitor Y2 by oxime bond formation (Fig. 2).
Purification of Yapsin 1 by Affinity Chromatography--
Yapsin 1 was expressed and secreted into the culture medium of a yeast
expression system, which has been described previously (11, 17). After
concentration of the medium by anion exchange chromatography using
DEAE-Sepharose beads, the sample was applied to the inhibitor column.
All of the yapsin 1 that was present in the starting material (Fig.
4A, lane S) bound
to the column as evidenced by the absence of any immunoreactive yapsin
1 in the flow through fraction (Fig. 4A, lane FT)
or any of the wash fractions. The yapsin 1 remained bound even during
the stringent second wash containing 0.5 M NaCl (Fig.
4A, 2nd wash). The yapsin 1 was eluted from the
inhibitor column by changing the pH from 4.0 to 8.5 and by including 2 M LiBr in the eluant (Fig. 4A, elution 1-9). Consistent with the elution profile of immunoreactive
yapsin 1, yapsin 1 enzymatic activity was demonstrated in the eluate as
seen by the generation of syn-Enk from pro-Enk (Fig. 4B,
elution 1-9). Note that in the absence of immunoreactive
yapsin 1 in the flow through and first three wash fractions, pro-Enk
was presumably degraded by other proteases present in the culture
supernatant that did not bind to the column.
|
Analysis of Affinity-purified Yapsin 1--
Fractions 2-9 of the
eluate were combined and concentrated. By Western blot analysis, the
purified yapsin 1 gave two bands at ~90 and 120-150 kDa,
corresponding to glycosylated yapsin 1 (17) (Fig.
5B, lane ). Upon
deglycosylation by endoglycosidase H treatment, a single immunoreactive
anti-yapsin 1 band is seen by Western blot (Fig. 5B,
lane +), and only one band is apparent by silver stain
analysis (Fig. 5C, lane +), indicating that the purity of the enzyme approached homogeneity. An aliquot of the starting
material (~10 µg) was analyzed by Coomassie Blue staining in which
yapsin 1 can be seen in addition to other proteins (Fig. 5A,
lane S). Using the quenched fluorescent substrate, specific activity assays for the starting material and the purified yapsin 1 yielded 95 and 752 units/µg/min, respectively, indicating a fold
purification of ~8.
|
Inhibition of Sap9p Cleavage of Proenkephalin by
Y1--
Sap9p was expressed and secreted into the culture medium
of a P. pastoris expression system. Coomassie Blue staining
(not shown) confirmed the presence of Sap9p in the induced medium and its absence in the uninduced medium, whereas activity assays using adrenocorticotropin hormone1-39 as a substrate
confirmed that Sap9p can cleave at basic residue cleavage
sites.2 Sap9p was shown here to process the prohormone,
pro-Enk, to generate syn-Enk (Fig. 6,
lane 1). This activity was inhibited by pepstatin A (Fig. 6,
lane 5) as well as by Y1 in a
dose-dependent manner. At 100 µM of
Y1, almost complete inhibition of the Sap9p activity was
observed (Fig. 6, lane 2), whereas at 10 µM,
~50% inhibition was observed (Fig. 6, lane 3), and at 1 µM almost no inhibition was observed (Fig. 6, lane
4).
|
Purification of Sap9p by Affinity Chromatography--
Sap9p was
purified from the conditioned medium of a P. pastoris
expression system. The enzyme specifically eluted from the column in
fractions E2 and E3, as measured by the disappearance of pro-Enk
substrate and the generation of syn-Enk product in the assay of these
fractions (Fig. 7). The smaller band of
syn-Enk observed in E2 is consistent with syn-Enk (1-74),
i.e. syn-Enk-Lys, and the slightly bigger product band in E3
is consistent with a Met-enkephalin extended form of syn-Enk, syn-Enk
(1-82), i.e. syn-Enk-Lys-Lys-Tyr-Gly-Gly-Phe-Met-Lys-Arg82.
Products with similar mobility on SDS-PAGE were generated by purified
yapsin 1 and identified by mass spectroscopy as syn-Enk (1-74) and
syn-Enk (1-82).2 Coomassie stain analysis of the
concentrated eluted Sap9p showed two major bands (Fig.
8): one band at an apparent molecular
mass of ~60 kDa and one band at an apparent molecular mass of ~5
kDa. N-terminal amino acid sequence analysis of the upper band gave the
following sequence beginning with Leu154,
L-F-G-F-G-X-I-Y. The lower band gave the following sequence starting with Asp51,
D-G-S-L-D-M-T-L-T-N-K-Q-T-F-Y. This demonstrated that Sap9p exists as a
heterodimer and confirms the predicted pro-region processing site as
Lys49-Arg50. The site where cleavage occurs to
generate the two subunits in Sap9p is equivalent to the position where
yapsin 1 is cleaved to generate its two subunits. However, because of
the apparent size of the smaller band (~5 kDa), it is likely that
additional processing has occurred on its carboxyl end to generate a
protein of this size instead of one of the expected size, ~10 kDa
(amino acids 51-153). We propose to call the Sap9p subunits and
, in keeping with the similar nomenclature used for yapsin 1.
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Yapsin 1 is the model enzyme for the new subclass of aspartyl proteases that cleave proproteins at specific basic residue cleavage sites. Extensive analyses of its specificity (15, 22-24) have revealed that substrates containing multiple basic residues surrounding the scissile bond are cleaved with high efficiencies. The nature of this specificity is not completely understood even though molecular modeling (Protein Data Bank code 1YPS) (24) has revealed that yapsin 1 has a more open active site compared with other aspartyl proteases and that many of its subsites are electronegative, thus allowing for the accommodation of positively charged residues within and surrounding the cleavage site (24). We have attempted to crystallize yapsin 1 to obtain x-ray crystal structure data but have been unsuccessful. The main problem resided in the high degree of glycosylation added to yapsin 1 in the yeast, ranging from 50 to 300% of its calculated molecular mass. Removal of this excess sugar can be achieved readily by endoglycosidase H or N-glycanase treatment; however, under these conditions, the deglycosylated yapsin 1 is not sufficiently stable for crystals to form.
To solve this problem we have synthesized an inhibitor of yapsin 1 that
could be used in co-crystallization studies with deglycosylated yapsin
1. The design of the inhibitor Y1 (Fig. 1, compound 1) was based on the sequence of a
cholecystokinin13-33 analog that yapsin 1 was shown
to cleave with relatively high efficiency (5.2 × 105
M1 s
1) (24). The sequence of
this peptide surrounding the scissile bond was RVSMIKNR, where cleavage
occurred on the carboxyl side of the single lysine residue. Evaluation
of peptide analogs demonstrated that for good cleavage
efficiency, basic residues should be present at the P1, P6, and
especially P2' positions (24). Therefore, the key inhibitor design
feature was to replace the scissile Lys-Asn dipeptide in the peptide
substrate with the stable hydroxyethylamine peptide isostere that
incorporated a lysine side chain at the P1 position (Fig. 1). Notably,
the hydroxyethylamine isostere serves as a very effective pharmacophore
for inhibiting aspartyl proteases as demonstrated by several approved
HIV-1 protease inhibitors that incorporate this isostere. To further
take advantage of the known octamer substrate structure activity
relationships, a small collection of potential inhibitors, was prepared
by parallel synthesis with basic functionality introduced at the P2'
position as introduced by the R1 and R2 diversity elements. Screening
the compound collection for inhibition of yapsin 1 resulted in the
identification of inhibitor Y1 (Fig. 1).
Using the quenched fluorescent substrate, Y1 was shown to inhibit purified yapsin 1 with an apparent Ki of 64.5 nM (Fig. 3), and its mechanism of inhibition is characteristic of competitive inhibition. Its inhibitory property was maintained after coupling to agarose beads as seen by the ability of the inhibitor column to bind and elute yapsin 1, demonstrating that enzyme-inhibitor binding was reversible (Figs. 4 and 5). We estimate that with 10 µmol of inhibitor coupled to the beads, its capacity, even at 10% (i.e. 1µmole availability), would be sufficient to purify >10 mg of yapsin 1. As expected from conditioned medium that is enriched in yapsin 1 (Fig. 5A, lane S), the purification procedure resulted in only an ~8-fold increase in specific activity as measured by the quenched fluorescent substrate.
In the yeast S. cerevisiae, there are three members of the yapsin family that not only share sequence identity but also cleavage specificity. However, whereas each enzyme can cleave at basic residues, they exhibit some differences. For example, yapsin 1 cleaves adrenocorticotropin hormone1-39 at its tetra-basic residue cleavage site extremely well, whereas yapsin 3 does not appear to cleave it at all (6). It is because of this selective specificity that a broad range of heterologously expressed proteins in S. cerevisiae are cleaved in a limited way by these enzymes (25, 26). To circumvent this problem, researchers have utilized yeast mutants that lack either yapsin 1 (27-29) or both yapsin 1 and 2 (25, 30) to express their proteins. However, although recovery of intact protein increases in this double mutant, the overall yield may be limited because this mutant exhibits impaired growth at 37 °C (5). Because the yapsins are GPI membrane-anchored proteases located on the extracellular side of the cell membrane (5, 17, 31), addition of specific and potent yapsin inhibitors to the culture medium may be an alternative approach to minimize proteolysis while maximizing the expression potential from wild type yeast.
This new inhibitor described here also inhibited Sap9p (Fig. 6), a secreted aspartyl protease from C. albicans. In addition, Sap9p was purified from conditioned medium by affinity chromatography using the inhibitor column (Figs. 7 and 8). The ability to specifically inhibit Sap9p may prove worthwhile in the prevention or impairment of the virulence of C. albicans, an opportunistic yeast prevalent in immuno-compromised patients. This is because all the SAP enzymes described so far have a paired basic cleavage site in their pro-region (7) that is predicted to be cleaved by an appropriate enzyme to generate the mature SAPs that are subsequently involved in virulence (32). Although this paired basic amino acid motif is described as a Kex2p cleavage site, it is not known with certainty what enzyme actually performs this function in vivo. In Kex2p-null mutants of C. albicans, the activation of Sap2p still occurs, albeit at reduced levels (33), demonstrating that another enzyme is involved in this activation, speculated previously to be Sap9p (7). If Sap9p, which exhibits specificity for this type of motif, is involved in the maturation of some or all of the SAPs, then inhibition of Sap9p may represent a pivotal step in the prevention of virulence of this pathogen.
Our sequencing results of the purified Sap9p showed a distinct
similarity to yapsin 1 with respect to its processing into two
subunits. Processing of Sap9p into its two subunits occurs after a
single Lys residue, Lys153, that aligns almost exactly with
the subunit cleavage site of yapsin 1 and occurs within a loop
insertion which, when compared with other aspartyl proteases, seems to
be unique to yapsin 1, yapsin 2, and Sap9p. The mature N-terminal amino
acid of the subunit was determined to be Asp51,
confirming the prediction that the pro-region cleavage site occurred
after the pair of basic residues, Lys49-Arg50.
It is not known whether a pseudo-Sap9p is generated during activation similar to yapsin 1 (11).
We have provided here the first report of a potent inhibitor of the
novel class of basic residue-specific aspartyl proteases. The inhibitor
Y1 should serve as a powerful chemical tool for the study of
the increasing number of yapsin-like enzymes in the same way that
pepstatin has been essential for the study of more traditional aspartyl
proteases. In particular, we plan to obtain co-crystals of
Y1 with yapsin 1 to enable x-ray structure determination. In
addition, inhibitor-coupled agarose beads are effective for rapid
purification of yapsin-like enzymes and may prove useful for the
identification and purification of additional yapsin-like enzymes from
other eukaryotic species. Finally, further optimization of
Y1 could provide useful compounds for the inhibition of
potentially critical proteases involved in pathogenic mechanisms.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Dr. Michel Monod (Lausanne, Switzerland) for the P. pastoris expression system of Sap9p and Dr. Iris Lindberg (Louisiana State University Health Sciences Center, New Orleans, LA) for the mammalian expression system for rat proenkephalin. We also thank Dr. Hao-Chia Chen (Endocrinology and Reproduction Research Branch, NICHD, National Institutes of Health) for N-terminal amino acid sequencing of Sap9p.
![]() |
FOOTNOTES |
---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at
http://www.jbc.org) contains supplemental text.
§ To whom correspondence should be addressed: 49 Convent Dr., MSC 4480, Bldg. 49/5A38, Bethesda, MD 20892. Tel.: 301-435-8920; Fax: 301-435-9141; E-mail: cawleyn@mail.nih.gov.
Supported by National Institutes of Health Grant GM54051.
Published, JBC Papers in Press, December 4, 2002, DOI 10.1074/jbc.M207230200
2 N. X. Cawley, unpublished data.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: DMF, N,N-dimethylformamide; NMP, N-methylpyrrolidinone; Fmoc, N-(9-fluorenyl)methoxycarbonyl; HPLC, high pressure liquid chromatography; MES, 4-morpholineethanesulfonic acid; pro-Enk, proenkephalin; syn-Enk, syn-enkephalin; HIV-1, human immunodeficiency virus, type 1; Sap9p, secreted aspartyl protease 9.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Egel-Mitani, M., Flygenring, H. P., and Hansen, M. T. (1990) Yeast 6, 127-137[Medline] [Order article via Infotrieve] |
2. | Julius, D., Brake, A., Blair, L., Kunisawa, R., and Thorner, J. (1984) Cell 37, 1075-1089[Medline] [Order article via Infotrieve] |
3. | Dunn, B. M., Jimenez, M., Parten, B. F., Valler, M. J., Rolph, C. E., and Kay, J. (1986) Biochem. J. 237, 899-906[Medline] [Order article via Infotrieve] |
4. | Cawley, N. X., and Loh, Y. P. (2003) in Handbook of Proteolytic Enzymes (Barrett, A. J. , and Woessner, F., eds), 2nd Ed. , Academic Press, London, in press |
5. | Komano, H., and Fuller, R. S. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10752-10756[Abstract] |
6. | Olsen, V., Cawley, N. X., Brandt, J., Egel-Mitani, M., and Loh, Y. P. (1999) Biochem. J. 339, 407-411[CrossRef][Medline] [Order article via Infotrieve] |
7. | Monod, M., Hube, B., Hess, D., and Sanglard, D. (1998) Microbiology 144, 2731-2737[Abstract] |
8. | Loh, Y. P., and Cawley, N. X. (2003) in Handbook of Proteolytic Enzymes (Barrett, A. J. , and Woessner, F., eds), 2nd Ed. , Academic Press, London, in press |
9. |
Loh, Y. P.,
Parish, D. C.,
and Tuteja, R.
(1985)
J. Biol. Chem.
260,
7194-7205 |
10. |
Azaryan, A. V.,
Wong, M.,
Friedman, T. C.,
Cawley, N. X.,
Estivariz, F. E.,
Chen, H. C.,
and Loh, Y. P.
(1993)
J. Biol. Chem.
268,
11968-11975 |
11. |
Cawley, N. X.,
Olsen, V.,
Zhang, C. F.,
Chen, H. C.,
Tan, M.,
and Loh, Y. P.
(1998)
J. Biol. Chem.
273,
584-591 |
12. | Cawley, N. X. (1995) Characterization of Yeast Aspartic Protease 3: A Novel Basic-Residue Specific Prohormone Processing Enzyme.Ph.D. Thesis , Biochemistry Department, Uniformed Services University of the Health Sciences, Bethesda, MD |
13. | Angliker, H., Neumann, U., Molloy, S. S., and Thomas, G. (1995) Anal. Biochem. 224, 409-412[CrossRef][Medline] [Order article via Infotrieve] |
14. |
Hatsuzawa, K.,
Nagahama, M.,
Takahashi, S.,
Takada, K.,
Murakami, K.,
and Nakayama, K.
(1992)
J. Biol. Chem.
267,
16094-16099 |
15. |
Cawley, N. X.,
Chen, H.-C.,
Beinfeld, M. C.,
and Loh, Y. P.
(1996)
J. Biol. Chem.
271,
4168-4176 |
16. | Bakker, A. V., Jung, S., Spencer, R. W., Vinick, F. J., and Faraci, W. S. (1990) Biochem. J. 271, 559-562[Medline] [Order article via Infotrieve] |
17. | Cawley, N. X., Wong, M., Pu, L.-P., Tam, W., and Loh, Y. P. (1995) Biochemistry 34, 7430-7437[Medline] [Order article via Infotrieve] |
18. | Lindberg, I., and Zhou, Y. (1995) Methods Neurosci. 23, 94-108 |
19. | Fernandez-Garcia, C., and McKervey, M. A. (1995) Tetrahedron Asymmetry 6, 2905-2906[CrossRef] |
20. | Thompson, L. A., and Ellman, Jonathan A. (1994) Tetrahedron Lett. 35, 9333-9336[CrossRef] |
21. | Kick, E. K., and Ellman, J. A. (1995) J. Med. Chem. 38, 1427-1430[Medline] [Order article via Infotrieve] |
22. | Ledgerwood, E. C., George, P. M., Peach, R. J., and Brennan, S. O. (1995) Biochem. J. 308, 321-325[Medline] [Order article via Infotrieve] |
23. | Ledgerwood, E. C., Brennan, S. O., Cawley, N. X., Loh, Y. P., and George, P. M. (1996) FEBS Lett. 383, 67-71[CrossRef][Medline] [Order article via Infotrieve] |
24. | Olsen, V., Guruprasad, K., Cawley, N. X., Chen, H. C., Blundell, T. L., and Loh, Y. P. (1998) Biochemistry 37, 2768-2777[CrossRef][Medline] [Order article via Infotrieve] |
25. | Copley, K. S., Alm, S. M., Schooley, D. A., and Courchesne, W. E. (1998) Biochem. J. 330, 1333-1340[Medline] [Order article via Infotrieve] |
26. | Bourbonnais, Y., Larouche, C., and Tremblay, G. M. (2000) Protein Expression Purif. 20, 485-491[CrossRef][Medline] [Order article via Infotrieve] |
27. | Kerry-Williams, S. M., Gilbert, S. C., Evans, L. R., and Ballance, D. J. (1998) Yeast 14, 161-169[CrossRef][Medline] [Order article via Infotrieve] |
28. | Kang, H. A., Kim, S. J., Choi, E. S., Rhee, S. K., and Chung, B. H. (1998) Appl. Microbiol. Biotechnol. 50, 187-192[CrossRef][Medline] [Order article via Infotrieve] |
29. | Song, G. Y., and Chung, B. H. (2000) Process. Biochem. 35, 503-508 |
30. | Zhang, W., Espinoza, D., Hines, V., Innis, M., Mehta, P., and Miller, D. L. (1997) Biochim. Biophys. Acta 1359, 110-122[Medline] [Order article via Infotrieve] |
31. |
Ash, J.,
Dominguez, M.,
Bergerson, J. J.,
Thomas, D. Y.,
and Bourbonnais, Y.
(1995)
J. Biol. Chem.
270,
20847-20854 |
32. |
Naglik, J. R.,
Newport, G.,
White, T. C.,
Fernandes-Naglik, L. L.,
Greenspan, J. S.,
Greenspan, D.,
Sweet, S. P.,
Challacombe, S. J.,
and Agabian, N.
(1999)
Infect. Immun.
67,
2482-2490 |
33. |
Newport, G.,
and Agabian, N.
(1997)
J. Biol. Chem.
272,
28954-28961 |
34. | Borg-von Zepelin, M., Beggah, S., Boggian, K., Sanglard, D., and Monod, M. (1998) Mol. Microbiol. 28, 543-554[CrossRef][Medline] [Order article via Infotrieve] |